Imaging and Chemotherapeutic Comparisons of Iron Oxide Nanoparticles Chemically and Physically Coated with Poly(ethylene glycol)-b-Poly(ε-caprolactone)-g-Poly(acrylic acid).
We designed a new copolymer, poly(ethylene glycol)-block-poly(ε-caprolactone)-graft-poly(acrylic acid) (PAA-PEC), which could be chemically and physically coated onto iron oxide (Fe3O4) nanoparticles for theranostic applications. The chemically PAA-PEC-coated Fe3O4 nanoparticles (PAA-PEC-IO) were prepared using the carboxylic groups of PAA-PEC to bind the Fe3O4 nanoparticles during a co-precipitation reaction. Because of the amphiphilic properties of PAA-PEC, the compound self-assembled into a core-shell structure. The hydrophobic oleic acid-coated Fe3O4 nanoparticles could then be physically encapsulated inside the hydrophobic core of PAA-PEC (PAA-PEC-OA-IO) using an emulsion technique. A similar amount of iron content was controlled in both the PAA-PEC-IO and PAA-PEC-OA-IO (-23%). The particle diameters, morphologies, superparamagnetism, drug loading efficiency, and transversal relaxivity (r2) were studied and compared between the two magnetic nanoparticles. All results displayed the chemically-synthesized PAA-PEC-IO nanoparticles had higher potential than did the physically-synthesized PAA-PEC-OA-IO as an MRI contrast agent and a drug delivery carrier. Rodamine123-linked PAA-PEC-IO (PAA-PEC-IO-Rh123) was used as a molecular probe. Flow cytometric diagrams indicated that cellular internalization of PAA-PEC-IO occurred primarily through clathrin-mediated endocytosis.
Guo-Jing
GJ
Chen
Chin
C
Hsu
Jyun-Han
JH
Ke
Li-Fang
LF
Wang
D000180:Acrylic Resins / Q000737:chemistry* / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000008:administration & dosage* / Q000493:pharmacokinetics; D020099:Coated Materials, Biocompatible / Q000138:chemical synthesis / Q000737:chemistry / Q000627:therapeutic use; D004318:Doxycycline / Q000008:administration & dosage / Q000493:pharmacokinetics; D004337:Drug Carriers / Q000138:chemical synthesis* / Q000737:chemistry / Q000627:therapeutic use*; D016503:Drug Delivery Systems; D004354:Drug Screening Assays, Antitumor; D005290:Ferric Compounds / Q000737:chemistry*; D005434:Flow Cytometry / Q000379:methods; D006801:Humans; D058185:Magnetite Nanoparticles / Q000737:chemistry* / Q000627:therapeutic use; D010078:Oxazines / Q000008:administration & dosage / Q000493:pharmacokinetics; D011091:Polyesters / Q000737:chemistry* / Q000627:therapeutic use; D017550:Spectroscopy, Fourier Transform Infrared; D014407:Tumor Cells, Cultured
D000180:Acrylic Resins; D000970:Antineoplastic Agents; D020099:Coated Materials, Biocompatible; D004337:Drug Carriers; D005290:Ferric Compounds; D058185:Magnetite Nanoparticles; D010078:Oxazines; D011091:Polyesters; C556908:poly(ethylene glycol)-b-(epsilon-caprolactone)-b-poly(acrylic acid); C000499:ferric oxide; D004318:Doxycycline; C044808:nile red